By Pritam Biswas

(Reuters) – LB Pharmaceuticals’ shares rose 27% in their Nasdaq debut on Thursday, giving the biotech firm a valuation of $381.9 million and opening the door for companies looking to tap the public markets before 2026.

Shares of the New York-based company opened at $19 apiece, compared with its IPO price of $15. It had priced its offering within its marketed range to raise $285 million.

Activity in the U.S. IPO market has bumped up going into the fall season as investors shrugged off tariff concerns that jolted the market earlier in the year.

“Tariffs haven’t been a major sticking point, with the S&P 500 hitting all-time highs; a little early-September volatility is healthy, bringing valuations to more attractive levels for new investors,” said Jeff Zell, senior resear

See Full Page